 SAN DIEGO, June 24, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a clinical-stage targeted oncology company, announced today that the U.S. Food and Drug Administration FDA has granted Breakthrough Therapy Designation to adagrasib for the potential treatment of patients with non-small cell lung cancer NSCLC who harbor the KRASG12C mutation following prior systemic therapy. Breakthrough Therapy Designation is an FDA program designed to expedite the development and regulatory review of drugs that have demonstrated preliminary clinical evidence of a substantial improvement over available therapy in the treatment of patients with serious diseases on at least one clinically significant endpoint. 